List of investigational antidepressants

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. All drugs listed are specifically under development for major depressive disorder (MDD) and/or treatment-resistant depression (TRD) unless noted otherwise. Other forms of depression may include bipolar depression and postpartum depression.

Glutamatergics[edit]

NMDA receptor modulators[edit]

AMPA receptor modulators[edit]

Monoaminergics[edit]

Monoamine reuptake inhibitors[edit]

Monoamine reuptake inhibitors and receptor modulators[edit]

Monoamine releasing agents[edit]

Monoamine receptor modulators[edit]

Atypical antipsychotics[edit]

  • Brilaroxazine (RP-5063, RP-5000) – AA – specifically under development for the treatment of MDD[18]
  • Cariprazine (Reagila, Vraylar) – AA – approved for bipolar depression, under development for MDD [13]
  • Lumateperone (ITI-007) – AA – specifically under development for the treatment of MDD and bipolar depression[19]
  • Lurasidone (Latuda) – AA – specifically under development for the treatment of MDD [14]
  • Pimavanserin (Nuplazid; ACP-103; BVF-048) – 5-HT2A receptor antagonist – specifically under development for the treatment of MDD[20]

Others[edit]

GABAergics and neurosteroids[edit]

GABAA receptor positive modulators[edit]

  • PRAX-114 – GABAA receptor positive allosteric modulator [15]
  • Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of MDD and postpartum depression[22]

Others[edit]

Opioidergics[edit]

κ-Opioid receptor antagonists[edit]

Nociceptin receptor antagonists[edit]

Cholinergics[edit]

Muscarinic acetylcholine receptor modulators[edit]

Others[edit]

Orexin receptor antagonists[edit]

Others[edit]

Mixed[edit]

Combinations[edit]

Not under development[edit]

The following notable drugs are of investigational interest as potential antidepressants but are not formally under clinical development for approval at this time:

See also[edit]

References[edit]

  1. ^ "AV 101". adisinsight.springer.com. Retrieved 7 May 2017.
  2. ^ "Apimostinel". adisinsight.springer.com. Retrieved 7 May 2017.
  3. ^ a b Hashimoto, Kenji (2019). "Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective". Psychiatry and Clinical Neurosciences. 73 (10): 613–627. doi:10.1111/pcn.12902. ISSN 1323-1316. PMC 6851782. PMID 31215725.
  4. ^ "Arketamine - Jiangsu Hengrui Medicine - AdisInsight".
  5. ^ "Dextromethadone - Relmada Therapeutics". adisinsight.springer.com. Retrieved 10 November 2018.
  6. ^ "Ketamine intranasal - Vyera Pharmaceuticals". adisinsight.springer.com. Retrieved 7 May 2017.
  7. ^ "CERC 301". adisinsight.springer.com. Retrieved 7 May 2017.
  8. ^ "AGN 241751 - AdisInsight". adisinsight.springer.com. Retrieved 2022-05-12.
  9. ^ "PDC-1421". adisinsight.springer.com. Retrieved 24 March 2018.
  10. ^ "LY 03005". adisinsight.springer.com. Retrieved 7 May 2017.
  11. ^ "FKB 01MD". adisinsight.springer.com. Retrieved 7 May 2017.
  12. ^ "SEP 4199 - AdisInsight".
  13. ^ Hopkins SC, Wilkinson S, Corriveau TJ, Nishikawa H, Nakamichi K, Loebel A, Koblan KS (May 2021). "Discovery of Non-racemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders". Clin Pharmacol Ther. 110 (3): 808–815. doi:10.1002/cpt.2282. PMC 8453756. PMID 33961287.
  14. ^ "Gepirone ER". adisinsight.springer.com. Retrieved 7 May 2017.
  15. ^ "Pramipexole - Chase Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
  16. ^ "Product Discovery and Development". Chase Therapeutics. Retrieved 2020-01-25.
  17. ^ "Psilocybin". adisinsight.springer.com. Retrieved 26 October 2018.
  18. ^ "RP 5063". adisinsight.springer.com. Retrieved 7 May 2017.
  19. ^ "Lumateperone". adisinsight.springer.com. Retrieved 7 May 2017.
  20. ^ "Pimavanserin". adisinsight.springer.com. Retrieved 25 September 2017.
  21. ^ "Ademetionine". adisinsight.springer.com. Retrieved 7 May 2017.
  22. ^ "SAGE 217". adisinsight.springer.com. Retrieved 9 February 2018.
  23. ^ "Pregnenolone methyl ether". adisinsight.springer.com. Retrieved 7 May 2017.
  24. ^ "PH 10 nasal spray". adisinsight.springer.com. Retrieved 7 May 2017.
  25. ^ "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
  26. ^ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Retrieved 2020-01-25.
  27. ^ "Buprenorphine/samidorphan". adisinsight.springer.com. Retrieved 7 May 2017.
  28. ^ "BTRX-246040". adisinsight.springer.com. Retrieved 24 March 2018.
  29. ^ "Botulinum toxin A injectable - Allergan". adisinsight.springer.com. Retrieved 7 May 2017.
  30. ^ "JNJ 61393215 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
  31. ^ "A Study of JNJ-61393215 in the Treatment of Depression - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-01-25.
  32. ^ "JNJ 42847922". adisinsight.springer.com. Retrieved 7 May 2017.
  33. ^ "JNJ-54175446". adisinsight.springer.com. Retrieved 24 March 2018.
  34. ^ "NSI 189". adisinsight.springer.com. Retrieved 7 May 2017.
  35. ^ "NV 5138". adisinsight.springer.com. Retrieved 7 November 2018.
  36. ^ Duman RS (2018). "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide". F1000Research. 7: 659. doi:10.12688/f1000research.14344.1. PMC 5968361. PMID 29899972.
  37. ^ Duman R, Kato T, Liu RJ, Duman C, Terwilliger R, Vlasuk G, Hahm S, Sajah E (November 2017). "Sestrin 2 Modulator NV-5138 Shows Ketamine-Like Rapid Antidepressant Effects via Direct Activation of mTORC1 Signaling" (PDF). Neuropsychopharmacology. 43: S195. doi:10.1038/npp.2017.264.
  38. ^ "TS 121". adisinsight.springer.com. Retrieved 7 May 2017.
  39. ^ "Xenon Pharmaceuticals".
  40. ^ "Tramadol controlled release - e-Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
  41. ^ "Another depression drug flops as e-Therapeutics tallies PhIIb data - FierceBiotech". www.fiercebiotech.com. 15 February 2016. Retrieved 28 August 2018.
  42. ^ "E-Therapeutics defends PhIIb fail, claiming drug has 'pretty much' the hoped-for profile - FierceBiotech". www.fiercebiotech.com. 17 February 2016. Retrieved 28 August 2018.
  43. ^ "Bupropion/dextromethorphan - Axsome Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
  44. ^ "Cycloserine/lurasidone - NeuroRx". adisinsight.springer.com. Retrieved 7 May 2017.
  45. ^ "Deudextromethorphan". adisinsight.springer.com. Retrieved 7 May 2017.
  46. ^ Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. (May 2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533 (7604): 481–6. Bibcode:2016Natur.533..481Z. doi:10.1038/nature17998. PMC 4922311. PMID 27144355. Lay summaryScienceDaily. {{cite journal}}: Cite uses deprecated parameter |lay-source= (help)
  47. ^ Rosenblat JD, McIntyre RS (February 2018). "Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials". Journal of Affective Disorders. 227: 219–225. doi:10.1016/j.jad.2017.10.042. PMID 29102836.
  48. ^ Cohen IV, Makunts T, Atayee R, Abagyan R (May 2017). "Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications". Scientific Reports. 7 (1): 1450. Bibcode:2017NatSR...7.1450C. doi:10.1038/s41598-017-01590-x. PMC 5431207. PMID 28469132.
  49. ^ Nagele P, Zorumski CF, Conway C (April 2018). "Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts". Journal of Clinical Psychopharmacology. 38 (2): 144–148. doi:10.1097/JCP.0000000000000837. PMC 5825282. PMID 29360650.
  50. ^ Lener MS, Kadriu B, Zarate CA (March 2017). "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression". Drugs. 77 (4): 381–401. doi:10.1007/s40265-017-0702-8. PMC 5342919. PMID 28194724.
  51. ^ Zorumski CF, Nagele P, Mennerick S, Conway CR (2015). "Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy". Frontiers in Psychiatry. 6: 172. doi:10.3389/fpsyt.2015.00172. PMC 4673867. PMID 26696909.
  52. ^ Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 115 (3): 578–583. doi:10.1073/pnas.1718683115. PMC 5777001. PMID 29295929.
  53. ^ Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM (November 2013). "Small molecules activating TrkB receptor for treating a variety of CNS disorders". CNS & Neurological Disorders Drug Targets. 12 (7): 1066–77. doi:10.2174/18715273113129990089. PMID 23844685.
  54. ^ Zhang JC, Yao W, Hashimoto K (2016). "Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets". Current Neuropharmacology. 14 (7): 721–31. doi:10.2174/1570159X14666160119094646. PMC 5050398. PMID 26786147.
  55. ^ Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5: 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.
  56. ^ Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". Journal of Medicinal Chemistry. 53 (23): 8274–86. doi:10.1021/jm101206p. PMC 3150605. PMID 21073191.
  57. ^ Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (October 2014). "Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation". The International Journal of Neuropsychopharmacology. 18 (4). doi:10.1093/ijnp/pyu077. PMC 4360225. PMID 25628381.
  58. ^ Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (December 2015). "Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression". Psychopharmacology. 232 (23): 4325–35. doi:10.1007/s00213-015-4062-3. PMID 26337614. S2CID 15076700.
  59. ^ Chang HA, Wang YH, Tung CS, Yeh CB, Liu YP (September 2016). "7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress". Psychiatry Investigation. 13 (5): 531–540. doi:10.4306/pi.2016.13.5.531. PMC 5067348. PMID 27757132.
  60. ^ Zhang MW, Zhang SF, Li ZH, Han F (December 2016). "7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress". Neuroscience Letters. 635: 33–38. doi:10.1016/j.neulet.2016.10.035. PMID 27773794. S2CID 157620.

Further reading[edit]

External links[edit]